Drug
Selinexor clinical trials
Also written KPT-330, Xpovio and ATG-010.
- studies test it
- 154
- open now
- 46
- in phase 3
- 14
- first study started
- 2012
Keep track of what changes. Save the selinexor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
154 studies that test it; most in 2014 (22)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 22 |
| 2015 | 19 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 11 |
| 2021 | 18 |
| 2022 | 12 |
| 2023 | 16 |
| 2024 | 11 |
| 2025 | 12 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 67
- Phase 2
- 101
- Phase 3
- 14
- Phase 4
- 1
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 38 · Other 116
Karyopharm Therapeutics Inc (29) · St. Jude Children's Research Hospital (5) · National Cancer Institute (NCI) (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · University Health Network, Toronto (4) · Antengene Corporation (4) · Memorial Sloan Kettering Cancer Center (4) · The First Affiliated Hospital of Soochow University (3)
Often tested with
Tested in the same studies.
Dexamethasone (20) · Lenalidomide (7) · Venetoclax (7) · Bortezomib (6) · Carfilzomib (5) · Daratumumab (5) · Pomalidomide (5) · Cytarabine (5)
Studies
Open first, then newest update. How each study uses selinexor is read from its arms, and is right about nine times in ten.
Testing it · 154
- Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentRecruitingPhase 1/2National Cancer Institute (NCI)NCT05432804Written as Selinexor
- A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05985161Written as Selinexor
- Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaRecruitingPhase 1Washington University School of MedicineNCT07200102Written as Selinexor
- Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05333458Written as Selinexor
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227Written as Selinexor
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as Selinexor 60 MG
- HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMRecruitingPhase 2Duke UniversityNCT06822972Written as Selinexor 40 mg
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2Natalie CallanderNCT07479979Written as Selinexor
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingPhase 1/2St. Jude Children's Research HospitalNCT06239272Written as Selinexor
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Selinexor
- The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 MutationsNot yet recruitingNot applicableBing HanNCT07632170Written as Selinexor
- Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative NeoplasmsNot yet recruitingPhase 2Zhongshan Hospital (Xiamen), Fudan UniversityNCT07626021Written as Selinexor
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07138209Written as Selinexor
- A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07574528Written as Selinexor
- Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 2Beijing Tongren HospitalNCT07554482Written as Selinexor
- Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin LymphomaRecruitingPhase 1/2Samsung Medical CenterNCT06552559Written as Selinexor
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingPhase 2John MascarenhasNCT07447817Written as Selinexor
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaRecruitingPhase 2University of MiamiNCT05530421Written as Selinexor
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Selinexor 60 mg
- Golidocitinib Combined With Selinexor for CAEBVDRecruitingPhase 2/3Beijing Friendship HospitalNCT07369739Written as Selinexor (combination therapy)
See all 154 studies that test selinexor →
Given in every arm · 13 — selinexor is usual care beside what is tested
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.RecruitingPhase 2Karyopharm Therapeutics IncNCT04414475Written as Selinexor
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Selinexor
- Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)RecruitingPhase 2Sun Yat-sen UniversityNCT06517511Written as Selinexor Oral Tablet [Xpovio]
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingPhase 2Juan DuNCT04941937Written as Selinexor
- Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialActive, not recruitingPhase 1/2Mayo ClinicNCT04764942Written as Selinexor
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnPhase 1/2Karyopharm Therapeutics IncNCT04607772Written as Selinexor
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedPhase 1M.D. Anderson Cancer CenterNCT02419495Written as Selinexor
- Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplantWithdrawnPhase 2Washington University School of MedicineNCT05820763Written as Selinexor
- Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic CancerCompletedPhase 1/2Mohammed Najeeb Al HallakNCT02178436Written as Selinexor
- Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1Alice MimsNCT02299518Written as selinexor
- Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor CancerCompletedPhase 1Karyopharm Therapeutics IncNCT01607905Written as Selinexor
- SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05093608Written as Selinexor Pill
- Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal CancerStatus unknownPhase 1Sheba Medical CenterNCT02137356Written as dose-escalated selinexor treatment
As the comparator · 4 — what is tested is compared with selinexor
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07623798Written as Selinexor Tablets
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07569757Written as Selinexor tablets
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaRecruitingPhase 3Chengdu Zenitar Biomedical Technology Co., LtdNCT07011056Written as Selinexor Tablets
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line TherapyTerminatedPhase 3Universitätsklinikum Hamburg-EppendorfNCT05675319Written as selinexor/bortezomib/dexamethasone (SVD)
Codes
What other systems call selinexor · ClinicalTrials.gg INT006398
- MeSH (NLM) C585161selinexorConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 31TZ62FO8FSELINEXORConfirmed FDA, NLM, Wikidata
- RxNorm 2178390One source FDA
- Wikidata Q27256082selinexorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102546SelinexorOne source FDA
- DrugBank DB11942One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585161 | selinexor | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 31TZ62FO8F | SELINEXOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2178390 | — | One source FDA |
| Wikidata | Q27256082 | selinexor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102546 | Selinexor | One source FDA |
| DrugBank | DB11942 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.